These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 9641189

  • 41. High performance liquid chromatography methods for studying protein binding of aluminium in human serum in the absence and in the presence of desferrioxamine.
    García Alonso JI, López García A, Pérez Parajón J, Blanco González E, Sanz Medel A, Cannata JB.
    Clin Chim Acta; 1990 Jul; 189(1):69-79. PubMed ID: 2383920
    [Abstract] [Full Text] [Related]

  • 42. Disturbance of cerebral function by aluminium in haemodialysis patients without overt aluminium toxicity.
    Altmann P, Dhanesha U, Hamon C, Cunningham J, Blair J, Marsh F.
    Lancet; 1989 Jul 01; 2(8653):7-12. PubMed ID: 2567838
    [Abstract] [Full Text] [Related]

  • 43. Removal of chelated aluminium during haemodialysis using polysulphone high-flux dialysers.
    Aarseth HP, Ganss R.
    Nephrol Dial Transplant; 1990 Jul 01; 5(11):942-4. PubMed ID: 2127830
    [Abstract] [Full Text] [Related]

  • 44. [Effect of desferrioxamine and deferiprone on osteocalcin secretion in osteoblast-type cells].
    González Suárez I, Fernández Martín JL, Naves Díaz M, Cannata Andía JB.
    Nefrologia; 2003 Jul 01; 23 Suppl 2():27-31. PubMed ID: 12778850
    [Abstract] [Full Text] [Related]

  • 45. [Treatment of aluminum-induced osteopathy with desferrioxamine in dialysis-dependent renal failure].
    Lechleitner P, Gmeiner R, Beck G, König P.
    Wien Med Wochenschr; 1987 Aug 15; 137(14-15):355-60. PubMed ID: 3673100
    [Abstract] [Full Text] [Related]

  • 46. Aluminium-related osteodystrophy and desferrioxamine treatment: role of phosphorus.
    Jorgetti V, Soeiro NM, Mendes V, Pereira RC, Crivellari ME, Coutris G, Borelli A, Leite MO, Nussenzweig I, Marcondes M.
    Nephrol Dial Transplant; 1994 Aug 15; 9(6):668-74. PubMed ID: 7970094
    [Abstract] [Full Text] [Related]

  • 47. Combined hemofiltration and desferrioxamine treatment for aluminum induced osteomalacia.
    Barré PE, Prichard S.
    Int J Artif Organs; 1986 May 15; 9(3):167-72. PubMed ID: 3733242
    [Abstract] [Full Text] [Related]

  • 48. Aluminum intoxication in a child: treatment with intraperitoneal desferrioxamine.
    Warady BA, Ford DM, Gaston CE, Sedman AB, Huffer WE, Lum GM.
    Pediatrics; 1986 Oct 15; 78(4):651-5. PubMed ID: 3763276
    [Abstract] [Full Text] [Related]

  • 49. Treatment of fracturing renal osteodystrophy by desferrioxamine.
    Ackrill P, Day JP, Garstang FM, Hodge KC, Metcalfe PJ, Benzo Z, Hill K, Ralston AJ, Ball J, Denton J.
    Proc Eur Dial Transplant Assoc; 1983 Oct 15; 19():203-7. PubMed ID: 6878234
    [Abstract] [Full Text] [Related]

  • 50. Exacerbation of aluminium encephalopathy after treatment with desferrioxamine.
    Lillevang ST, Pedersen FB.
    Nephrol Dial Transplant; 1989 Oct 15; 4(7):676. PubMed ID: 2510071
    [No Abstract] [Full Text] [Related]

  • 51. Anomalous rise of serum osteocalcin following desferrioxamine treatment in aluminium intoxication.
    Davie MW, Worsfold M, Sharp CA, Perks J, Day JP.
    Nephron; 1993 Oct 15; 65(2):245-8. PubMed ID: 8247187
    [Abstract] [Full Text] [Related]

  • 52. [Desferal treatment of aluminum poisoning; effect on serum concentrations of aluminum (Al), iron (Fe) and copper (Cu)].
    Günther K, Winnefeld K, Stein G, Sperschneider H, Schröter H, Fünfstück R.
    Z Urol Nephrol; 1986 Oct 15; 79(10):569-76. PubMed ID: 3811645
    [Abstract] [Full Text] [Related]

  • 53. [Accumulation of aluminum in the dialyzed patient: incidence, causes and possibilities of prevention].
    Sulková S, Laurincová Z, Lapcík O, Dlhopolcek P, Stodolová E, Komonová D.
    Cas Lek Cesk; 1989 Jan 02; 128(1):16-9. PubMed ID: 2713883
    [Abstract] [Full Text] [Related]

  • 54. [Use of the aluminum phosphate-binders in hemodialysis in the ultrapure water era].
    Arenas MD, Malek T, Gil MT, Moledous A, Núñez C, Alvarez-Ude F.
    Nefrologia; 2008 Jan 02; 28(2):168-73. PubMed ID: 18454706
    [Abstract] [Full Text] [Related]

  • 55. [Aluminum osteopathy--experience with therapy].
    Sulková S.
    Vnitr Lek; 1993 May 02; 39(5):459-63. PubMed ID: 8351877
    [Abstract] [Full Text] [Related]

  • 56. Desferrioxamine and hemofiltration for aluminum removal in patients on regular dialysis treatment.
    Segoloni G, Canavese G, D'Amicone M, Rubino GF, Scansetti G, Lamon S, Talarico S, Luda E, Vercellone A.
    Clin Nephrol; 1983 Aug 02; 20(2):105-8. PubMed ID: 6616975
    [No Abstract] [Full Text] [Related]

  • 57. Accumulation of aluminium in patients with acute renal failure.
    Davenport A, Roberts NB.
    Nephron; 1989 Aug 02; 52(3):253-8. PubMed ID: 2739864
    [Abstract] [Full Text] [Related]

  • 58. Studies of aluminium mobilization in renal dialysis patients using the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
    Kontoghiorghes GJ, Barr J, Baillod RA.
    Arzneimittelforschung; 1994 Apr 02; 44(4):522-6. PubMed ID: 8011008
    [Abstract] [Full Text] [Related]

  • 59. Chromatographic studies of aluminum-desferrioxamine complex in uremic patients.
    Canavese C, Pacitti A, Salomone M, Pramotton C, Segoloni G, Bedino S, Testore G, Lamon S, Vercellone A.
    ASAIO Trans; 1986 Apr 02; 32(1):367-9. PubMed ID: 3778736
    [No Abstract] [Full Text] [Related]

  • 60. Resistance to recombinant human erythropoietin due to aluminium overload and its reversal by low dose desferrioxamine therapy.
    Yaqoob M, Ahmad R, McClelland P, Shivakumar KA, Sallomi DF, Fahal IH, Roberts NB, Helliwell T.
    Postgrad Med J; 1993 Feb 02; 69(808):124-8. PubMed ID: 8506193
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.